SecBot SecBot
PRESS-RELEASE ·Filed May 4, 2026

CYTK

Cytokinetics, Incorporated
NEUTRAL
Impact 3/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Wait for topline results on May 5 before taking a position. Positive data could expand aficamten's label significantly, while negative results would be a major setback.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$77.09
T+0 close · May 4, 2026 · via day close
Latest settled
+4.32%
T+60 · $80.42
Vs SPY
+1.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $77.09entry
  2. T+1 · 7mo ago 0.00%α −1.38% · $77.09
  3. T+5 · 6mo ago −3.28%α −5.27% · $74.56
  4. T+20 · 6mo ago −8.02%α −12.97% · $70.91
  5. T+60 · 4mo ago +4.32%α +1.58% · $80.42
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Cytokinetics announced it will report topline results from its ACACIA-HCM trial (aficamten in non-obstructive HCM) on May 5, 2026, with a conference call to follow. No results were disclosed in this press release.

Key Facts

  • Topline results from Phase 3 ACACIA-HCM trial to be reported May 5, 2026
  • Trial evaluates aficamten in patients with non-obstructive hypertrophic cardiomyopathy
  • Conference call scheduled for 8:00 AM ET on May 5

Financial Impact

No financial data disclosed; impact depends on trial results

Risk Factors

  • Trial may fail to meet primary endpoint
  • Stock likely to be volatile around data release

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287103

Track record

46 reports on CYTK

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 4, 2026